New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For CAT;BMY From The Last 14 Days
Check below for free stories on CAT;BMY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 23, 2014
15:35 EDTCATNotable companies reporting before tomorrow's open
Subscribe for More Information
13:40 EDTCATEarnings Preview: Caterpillar sees Q1 revenue flat, year-over-year
Caterpillar (CAT) is expected to report first quarter earnings on Thursday, April 24, before the market open with a conference call scheduled for 11:00 am ET. Caterpillar is a manufacturer of mining and construction equipment. EXPECTATIONS: Analysts are looking for earnings per share of $1.24 on revenue of $13.14B, according to First Call. The consensus range for EPS is $1.03-$1.35 on revenue of $12.34B-$13.74B. LAST QUARTER: Caterpillar reported fourth quarter EPS of $1.54 against estimates for $1.28 on revenue of $14.4B against estimates for $13.64B. On its Q4 earnings report, the company forecast 2014 EPS ex. restructuring costs of $5.85, versus consensus of $5.78. FY14 revenue was seen at $56B, compared to consensus of $55.27B. In total, the company expects restructuring actions in 2014 to be about $400M-$500M and an after tax impact of 50c-60c per share. Caterpillar said it was seeing signs of improvement in the world economy. Despite the company's expectation that mine production will continue to increase, it expects mining companies to further reduce their capital expenditures in 2014. As a result, it expects sales in Resource Industries to decline modestly. The company said it will continue to be cautious on the mining industry. The company announced a $10B stock repurchase program that will expire on December 31, 2018, and it intends to repurchase $1.7B of common stock in Q1. On the company's Q4 conference call, management said it sees Q1 revenue flat with 1Q13. STREET RESEARCH: Sentiment on the Street has been mixed in the weeks leading up to Caterpillar's Q1 report. On February 20, Caterpillar was initiated with a Buy at Deutsche Bank with a price target of $122. Conversely, on March 4, Standpoint Research downgraded Caterpillar to Hold from Buy. PRICE ACTION: Caterpillar’s shares have traded approximately 14% higher since Q4 results were released in late January, and are up about 23% over the past year. In afternoon trading ahead of Thursday's Q1 report, Caterpillar’s shares are nearly flat.
10:51 EDTCATCaterpillar trends may be better than retail sales suggest, says Wells Fargo
Subscribe for More Information
10:44 EDTCATCaterpillar retail sales of machines for 3 months end March down 12%
Caterpillar disclosed in a regulatory filing earlier that its total retail sales of machines for the 3-month rolling period ended March were down 12%, which was down from an 8% decline reported for the 3-month period ended in February. In the March rolling period, retail machine sales were down 20% in Asia/Pacific, down 21% in EAME, down 21% in Latin America and up 6% in North America. Total Energy & Transportation retail sales for the March end rolling period were up 7%.
07:37 EDTBMYPeregrine announces investigator-sponsored combination trial with Bristol-Myers
Peregrine Pharmaceuticals (PPHM) announced the opening of an investigator-sponsored trial, or IST, of its investigational immunotherapy bavituximab in combination with Bristol-Myers Squibb's (BMY) ipilimumab, for the treatment of advanced melanoma. Bavituximab is an upstream immune checkpoint inhibitor that targets phosphatidylserine, or PS, a highly immunosuppressive molecule exposed on cells that line tumor blood vessels and tumor cells. Preclinical data in a model of melanoma demonstrate that the combination of a bavituximab equivalent and ipilimumab yield enhanced anti-tumor activity compared to ipilimumab alone. The trial is being conducted at the University of Texas Southwestern Medical Center, Dallas, and led by Arthur E. Frankel, M.D., Associate Professor of Internal Medicine at the Simmons Comprehensive Cancer Center. Bavituximab, Peregrine's lead immuno-oncology candidate, is being evaluated in second-line non-small cell lung cancer, as part of the SUNRISE pivotal Phase III clinical trial.
06:16 EDTBMYPharmaceutical companies narrowing focus, WSJ reports
Subscribe for More Information
April 22, 2014
19:03 EDTBMY Bristol-Myers and Samsung BioLogics to increase scope of existing agreement
Subscribe for More Information
14:47 EDTBMYOnglyza, Kombiglyze XR get Paragraph IV patent challenges
Subscribe for More Information
12:24 EDTCATBofA/Merrill industrial machinery analysts hold analyst/industry conference call
Subscribe for More Information
April 21, 2014
07:21 EDTBMYFDA Pediatric Advisory Committee to hold a meeting
The Committee discusses pediatric-focused safety reviews including MDT's Activa Dystonia Therapy, (BAX's Advate and Tisseel, NVS' Famvir, Tibotec's (JNJ subsidiary) Intelence, UCB Pharma's Keppra, MRK's Maxalt, BAYRY's Natazia, Digestive Care's Pertzye, JNJ's Prezista, BMY's Reyataz, SNY's Sklice, PFE's Torisel, Aptalis' Ultresa, and GILD's Viread in a meeting being held in Bethesda, Maryland on April 21 at 8 am. Webcast Link
April 20, 2014
16:53 EDTCATCaterpillar looks to halt production at facility in France, WSJ says
Subscribe for More Information
April 19, 2014
11:12 EDTBMYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
April 15, 2014
08:23 EDTBMYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:19 EDTBMYLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information
06:32 EDTBMYPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
April 14, 2014
08:15 EDTBMYBristol-Myers submits NDA for Reyataz-cobicistat combo for HIV-1
Bristol-Myers Squibb (BMY) announced the submission of a new drug application, or NDA, on April 4 to the FDA for a fixed-dose combination of atazanavir sulfate, a protease inhibitor marketed as Reyataz, and cobicistat, an investigational pharmacokinetic enhancer, or boosting agent, that can increase the level of certain HIV-1 medicines in the blood and make them more effective. Bristol-Myers Squibb is seeking approval of the fixed-dose combination tablet for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. If approved, atazanavir sulfate and cobicistat could offer patients living with HIV-1 a single tablet that eliminates the need to take a boosting agent in a separate tablet. Cobicistat is being developed by Gilead Sciences (GILD). Under the terms of a previously announced agreement, Bristol-Myers Squibb and its affiliates are responsible for the formulation, manufacturing, registration, distribution and commercialization of the atazanavir sulfate and cobicistat fixed-dose combination product worldwide. Gilead retains sole rights for the manufacture, development and commercialization of cobicistat as a stand-alone product and for use in combination with other agents.
April 10, 2014
07:04 EDTBMYBristol-Myers presents Phase III data on all-oral Daclatasvir and Asunaprevir
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use